Cannabis Compounds Show Potential to Reverse MASLD in One-Third of Adults

The recent revelation that cannabis-derived compounds could potentially reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) marks a significant pivot in the therapeutic application of cannabinoids. MASLD, formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), has become a silent epidemic, paralleling the rise of obesity and Type 2 diabetes. With approximately one-third of adults worldwide estimated to have some form of hepatic steatosis, the lack of targeted, effective treatments has created a massive unmet medical need. This new research suggests that specific non-psychoactive cannabinoids may interact with the body’s endocannabinoid system to not only halt but actively reduce the accumulation of fat in liver cells.

Industry context is crucial here, as the liver disease market has seen both high-profile failures and recent breakthroughs. Until the 2024 FDA approval of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom), there were no approved medications specifically for the advanced stages of this disease. The entry of cannabinoid-based therapies introduces a new biochemical pathway for treatment. While traditional pharmaceuticals often target thyroid hormone receptors or PPAR pathways, cannabinoids like CBD and THCV are being studied for their ability to modulate CB1 and CB2 receptors. Historically, CB1 activation was associated with increased fatty acid synthesis; however, new research focuses on peripheral CB1 antagonism or CB2 agonism, which appears to exert anti-inflammatory and anti-fibrotic effects without the psychiatric side effects associated with earlier generations of synthetic antagonists.

“

The recent revelation that cannabis-derived compounds could potentially reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) marks a significant pivot in the therapeutic application of cannabinoids.

The implications for the healthcare sector are twofold. First, this validates the shift from 'medical cannabis' as a broad wellness category toward 'cannabinoid-derived pharmaceuticals'—highly purified, regulated compounds that undergo rigorous clinical trials. For health systems and insurers, a successful treatment for MASLD could drastically reduce the long-term costs associated with liver cirrhosis, end-stage renal disease, and liver transplants. However, the short-term challenge remains the regulatory hurdle. The FDA maintains a strict stance on cannabis-derived products, requiring the same level of safety and efficacy data as any other synthetic drug. The precedent set by GW Pharmaceuticals’ Epidiolex for epilepsy provides a roadmap, but the scale of the MASLD patient population is exponentially larger, necessitating much more extensive Phase III trials.